Embla Medical hf.
OSSFF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $236,118 | $236,138 | $202,786 | $224,781 |
| % Growth | -0% | 16.4% | -9.8% | – |
| Cost of Goods Sold | $98,679 | $98,945 | $83,819 | $91,751 |
| Gross Profit | $137,439 | $137,193 | $118,967 | $133,030 |
| % Margin | 58.2% | 58.1% | 58.7% | 59.2% |
| R&D Expenses | $9,791 | $10,364 | $9,181 | $9,583 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $91,110 | $93,006 | $87,926 | $91,494 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$637 | $0 | $0 | $0 |
| Operating Expenses | $100,264 | $103,370 | $97,107 | $101,077 |
| Operating Income | $37,175 | $33,823 | $21,860 | $31,953 |
| % Margin | 15.7% | 14.3% | 10.8% | 14.2% |
| Other Income/Exp. Net | -$3,289 | -$5,706 | -$6,201 | -$7,071 |
| Pre-Tax Income | $33,887 | $28,117 | $15,659 | $24,882 |
| Tax Expense | $8,180 | $6,666 | $3,631 | $6,263 |
| Net Income | $25,789 | $21,246 | $12,158 | $18,206 |
| % Margin | 10.9% | 9% | 6% | 8.1% |
| EPS | 0.061 | 0.05 | 0.028 | 0.044 |
| % Growth | 21.2% | 78.6% | -36.4% | – |
| EPS Diluted | 0.061 | 0.05 | 0.028 | 0.044 |
| Weighted Avg Shares Out | 425,485 | 418,220 | 434,250 | 413,795 |
| Weighted Avg Shares Out Dil | 425,485 | 418,220 | 434,250 | 413,795 |
| Supplemental Information | – | – | – | – |
| Interest Income | $546 | $484 | $674 | $860 |
| Interest Expense | $6,217 | $5,150 | $5,250 | $5,724 |
| Depreciation & Amortization | $15,904 | $15,169 | $14,240 | $14,636 |
| EBITDA | $54,792 | $44,675 | $34,535 | $44,186 |
| % Margin | 23.2% | 18.9% | 17% | 19.7% |